Web1 mar 2024 · JCOG1104 (OPAS-1), an open-label, phase III, non-inferiority, randomized trial, showed that for patients with stage II GC, 4 cycles of S-1 were inferior to 8 cycles of … http://www.jcog.jp/document/s_1104.pdf
Survival analysis of stage II gastric cancer patients after D2 ...
Web29 ago 2024 · The Japan Clinical Oncology Group (JCOG) conducted the OPAS‐I (JCOG1104) trial, a Phase III study, to evaluate the overall efficacy of four courses of S‐1 adjuvant chemotherapy as compared to eight courses of the same regimen in patients who were diagnosed with pStage II after surgery. Web1 apr 2024 · Yoshikawa T, Terashima M, Mizusawa J, et al. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. Lancet Gastroenterol Hepatol 2024; 4: 208–16—In figure 1 of this Article, the number of patients who did not start treatment in … spurlin family tree
過去の臨床試験｜JCOG 胃がんグループ
Web7 ott 2024 · Recently, JCOG1104 trail further revealed the overall survival of stage II gastric cancer patients with eight course adjuvant S1 was better than those with four courses, but T1N2-3 and T3N0 were excluded . However, most patients in the INT-0116 study underwent D0 or D1 gastrectomy (a total of 90%). WebBackground: Guidelines recommend cognitive screening for all stroke survivors but do not suggest a preferred tool. Certain elements (orientation, executive function, language, and … Web18 set 2024 · The median treatment duration of postoperative chemotherapy was clearly shorter in CS (285 days in the S-1 group and 170 days in the CS group) following the standard treatment duration of adjuvant chemotherapy: S-1 for 1 year, and doublet chemotherapy for 6 months.10,16 The OPAS-1 trial (JCOG1104) failed to demonstrate … spurlin funeral home in lancaster ky